TY - JOUR
T1 - Antipneumolysin antibody titers in HIV-seropositive injection drug users before and after pneumococcal bacteremia
AU - Sullivan, Jeffrey H.
AU - Mitchell, Timothy J.
AU - Steinhoff, Mark C.
PY - 2001
Y1 - 2001
N2 - Lower baseline antipneumolysin antibody (α-PLY) levels have been found in populations with a higher incidence of pneumococcal infections. To determine whether predisease α-PLY titer is associated with invasive pneumococcal disease in HIV-seropositive injection drug users (IDU), we utilized a prospective cohort of IDU in Baltimore to compare α-PLY titers before bacteremia in 28 HIV-seropositive IDU cases with α-PLY titers in 56 matched (CD4 and seroconversion date) HIV-seropositive IDU control subjects and 28 matched (calendar time) HIV-seronegative IDU control subjects remaining free of pneumococcal disease. We also compared the postinfection fold-rise of α-PLY titers in cases relative to the change in α-PLY titers in control subjects during the same interval; α-PLY titers were measured using quantitative ELISA, and functional activity was assessed using antihemolysin assays. Predisease α-PLY titer did not differ between cases (66 units) and HIV-seropositive control subjects (70 units, p = 0.56) or HIV-seronegative control subjects (80 units, p = 0.10). There was a significant difference in fold-rise of α-PLY titers post-disease between cases (1.18) and HIV-seronegative control subjects (0.76), p = 0.03. Baseline α-PLY titers do not differ significantly between HIV-seropositive IDU who develop pneumococcal bacteremia from HIV-seropositive and HIV-seronegative IDU control subjects remaining free of severe pneumococcal disease.
AB - Lower baseline antipneumolysin antibody (α-PLY) levels have been found in populations with a higher incidence of pneumococcal infections. To determine whether predisease α-PLY titer is associated with invasive pneumococcal disease in HIV-seropositive injection drug users (IDU), we utilized a prospective cohort of IDU in Baltimore to compare α-PLY titers before bacteremia in 28 HIV-seropositive IDU cases with α-PLY titers in 56 matched (CD4 and seroconversion date) HIV-seropositive IDU control subjects and 28 matched (calendar time) HIV-seronegative IDU control subjects remaining free of pneumococcal disease. We also compared the postinfection fold-rise of α-PLY titers in cases relative to the change in α-PLY titers in control subjects during the same interval; α-PLY titers were measured using quantitative ELISA, and functional activity was assessed using antihemolysin assays. Predisease α-PLY titer did not differ between cases (66 units) and HIV-seropositive control subjects (70 units, p = 0.56) or HIV-seronegative control subjects (80 units, p = 0.10). There was a significant difference in fold-rise of α-PLY titers post-disease between cases (1.18) and HIV-seronegative control subjects (0.76), p = 0.03. Baseline α-PLY titers do not differ significantly between HIV-seropositive IDU who develop pneumococcal bacteremia from HIV-seropositive and HIV-seronegative IDU control subjects remaining free of severe pneumococcal disease.
UR - http://www.scopus.com/inward/record.url?scp=0035084342&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035084342&partnerID=8YFLogxK
U2 - 10.1164/ajrccm.163.3.2002066
DO - 10.1164/ajrccm.163.3.2002066
M3 - Article
C2 - 11254523
AN - SCOPUS:0035084342
SN - 1073-449X
VL - 163
SP - 680
EP - 684
JO - American journal of respiratory and critical care medicine
JF - American journal of respiratory and critical care medicine
IS - 3 I
ER -